[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Hukin J, Siffert J, Velasquez L, Zagzag D, Allen J: Leptomeningeal dissemination in children with progressive low-grade neuroepithelial tumors. Neuro Oncol; 2002 10;4(4):253-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal dissemination in children with progressive low-grade neuroepithelial tumors.
  • Our purpose is to describe the incidence and clinical features of leptomeningeal dissemination (LM) in children with progressive low-grade neuroepithelial tumor (LGN).
  • Satisfactorily followed data were obtained on 427 of the 588 patients with localized LGN at diagnosis between 1986 and 1998, 177 (42%) of whom developed progressive or recurrent disease.
  • The median age at initial diagnosis was 5 years and at LM diagnosis was 8.5 years.
  • The primary tumor sites were diencephalon (6), brainstem (3), cerebellum (2), cerebrum (1), and spinal cord (1).
  • Management included chemotherapy (2) or radiotherapy (3) or both (7); 1 patient received only radical resections of symptomatic lesions.
  • We strongly urge that for optimum treatment planning all patients with recurrent LGN be staged with an enhanced spine and brain MRI before adjuvant therapy is initiated.
  • The good survival of patients with LGN and LM reflects a more indolent disease than malignant CNS tumors with LM.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Meningeal Neoplasms / secondary. Neoplasms, Neuroepithelial / secondary
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Disease Progression. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / therapy. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12356355.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1920666
  •  go-up   go-down


2. Kim E, Bae TS, Kwon Y, Kim TH, Chung KW, Kim SW, Ro J, Lee ES: Primary malignant teratoma with a primitive neuroectodermal tumor component in thyroid gland: a case report. J Korean Med Sci; 2007 Jun;22(3):568-71
Genetic Alliance. consumer health - Teratoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant teratoma with a primitive neuroectodermal tumor component in thyroid gland: a case report.
  • However, the adult cases reported are mostly malignant and commonly arise in the thyroid.
  • Pathologic examination revealed it to be malignant teratoma composed of primitive neuroepithelial tissue with primitive neural tubes and loose myxoid to fibrous immature mesenchymal stroma.
  • The patient underwent extensive evaluation of the thyroid gland with computed tomography (CT) scan and positron emission tomography (PET) scan, which revealed no evidence of metastatic disease.
  • She underwent total thyroidectomy with bilateral modified radical neck dissection, intensive chemotherapy and radiotherapy.
  • This is the first case, to our knowledge, of malignant thyroid teratoma with a exuberant primitive neuroectodermal tumor component in Korea.
  • [MeSH-minor] Adult. Female. Head and Neck Neoplasms / pathology. Humans. Neoplasm Metastasis. Positron-Emission Tomography / methods. Thyroid Diseases / diagnosis. Thyroidectomy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Mar 1;88(5):1149-58 [10699906.001]
  • [Cites] Am J Otolaryngol. 2000 Mar-Apr;21(2):112-5 [10758996.001]
  • [Cites] Acta Cytol. 2000 May-Jun;44(3):375-9 [10833994.001]
  • [Cites] Ann Diagn Pathol. 2001 Oct;5(5):285-92 [11598856.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] Thyroid. 2003 Apr;13(4):401-4 [12804109.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):1015-22 [9818077.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2796-804 [7595741.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):896-904 [9255252.001]
  • [Cites] Am J Clin Oncol. 1998 Apr;21(2):212-4 [9537215.001]
  • [Cites] Ann Hematol. 1998 May;76(5):183-8 [9671130.001]
  • [Cites] Head Neck. 1998 Oct;20(7):649-53 [9744468.001]
  • [Cites] Bull Cancer. 1995;82 Suppl 1:56s-60s [7542945.001]
  • (PMID = 17596674.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2693658
  •  go-up   go-down


3. Kaji M, Takeshima H, Nakazato Y, Kuratsu J: Low-grade astroblastoma recurring with extensive invasion. Neurol Med Chir (Tokyo); 2006 Sep;46(9):450-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological examination showed the tumor cells were well differentiated with the perivascular pseudorosette pattern with broad, non-tapering processes radiating towards a central vessel without anaplastic features such as necrosis and endothelial proliferation.
  • The histological diagnosis was low-grade astroblastoma.
  • Second surgery was followed by adjuvant radiotherapy and combination chemotherapy.
  • Histological examination disclosed wide invasion by tumor cells into the subpial and perivascular space of the surrounding brain tissue.
  • Follow-up magnetic resonance imaging demonstrated further recurrence around the tumor cavity.
  • Surgical removal followed by six courses of combination chemotherapy (ifosfamide, cisplatin, and etoposide) resulted in complete remission of the tumor.
  • Although gross total resection of astroblastoma usually results in long-term survival, some of these yet unfamiliar tumors may develop a more malignant character.
  • [MeSH-major] Brain Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Neoplasms, Neuroepithelial / therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Humans. Male. Neoplasm Invasiveness. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Astroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998280.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Shim KW, Joo SY, Kim SH, Choi JU, Kim DS: Prediction of prognosis in children with medulloblastoma by using immunohistochemical analysis and tissue microarray. J Neurosurg Pediatr; 2008 Mar;1(3):196-205
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of prognosis in children with medulloblastoma by using immunohistochemical analysis and tissue microarray.
  • OBJECTIVES: Medulloblastoma is the most common malignant neuroepithelial tumor found in children.
  • METHODS: The data used were obtained in 58 patients with medulloblastoma who were > 3 years of age and in whom > 1 year of follow-up was available after the maximal resection, craniospinal irradiation, and chemotherapy treatments.
  • In addition, the authors tried to determine the prognostic utility of these results in this tumor category.
  • RESULTS: There was no statistically significant correlation between the prognosis and the degree of cell differentiation, but a positive correlation was noted between the PI and the AI in a tumor mass.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cerebellar Neoplasms / pathology. Medulloblastoma / pathology
  • [MeSH-minor] Adolescent. Adult. Apoptosis / physiology. Cell Differentiation / physiology. Cell Proliferation. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Forecasting. Humans. Immunohistochemistry. Male. Microarray Analysis. Neoadjuvant Therapy. Neoplasm Recurrence, Local / pathology. Prognosis. Radiotherapy, Adjuvant. Receptor, ErbB-3 / analysis. Receptor, trkC / analysis. Retrospective Studies. Treatment Outcome


5. Zhou WN, Chen ZP, You C, Mu YG, Sai K, Zhang JY, Zhang XH, Cheng JJ, Xu HC: [Individualized therapy and outcomes of microsurgery, radiotherapy, and chemotherapy for astrocytoma]. Ai Zheng; 2004 Nov;23(11 Suppl):1555-60
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Individualized therapy and outcomes of microsurgery, radiotherapy, and chemotherapy for astrocytoma].
  • BACKGROUND & OBJECTIVE: Astrocytomas, constitute about 75% of neuroepithelial tumors, is one of the most common primary tumors in central nervous system with fairly high incidence and poor prognosis.
  • This study was designed to investigate the efficiency of individualized treatment of microsurgery, radiotherapy, and chemotherapy for 62 patients with astrocytoma.
  • METHODS: Sixty-two patients with astrocytoma in study group were treated with individualized multimodality of microsurgery, postoperative radiotherapy, and/or postoperative chemotherapy according to in vitro sensitivity assay.
  • After microsurgery, 59 patients accepted radiotherapy, 46 patients received chemotherapy.
  • Fifty patients with astrocytoma in control group were treated with conventional treatment of surgery, chemotherapy, and radiotherapy.
  • After surgery, 31 patients received radiotherapy following by BCNU chemotherapy, while 19 patients accepted BCNU chemotherapy following radiotherapy.
  • Pathologic diagnosis of patients in study group were 19 cases of grade, 32 cases of grade III, and 11 cases of grade IV; in control group were 13 cases of grade II, 28 cases of grade III, and 9 cases of grade IV.
  • Mean follow-up time were 25.8 months, and the outcome was evaluated by MRI, KPS, and survival rate.
  • RESULTS: Tumor total resection rate in study group was 67.7%, while that in control group was 58.0%.
  • There was no significant difference of KPS and survival rate in patients with low-grade astrocytoma between 2 groups, while the outcome of patients with malignant astrocytoma was significantly improved by individualized treatment.
  • In glioblastoma patients, median survival time of study group was 18.68 months, while that of control group was 12.83 months (P< 0.01).
  • CONCLUSION: Individualized microsurgery may improve the total resection of astrocytoma, and benefit to postoperative treatment.Individualized radiotherapy/chemotherapy may prevent patients from some complications.
  • Individualized management may improve prognosis of patients with astrocytoma, particularly malignant astrocytoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / surgery. Brain Neoplasms / surgery. Microsurgery
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Female. Follow-Up Studies. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Glioblastoma / surgery. Humans. Male. Middle Aged. Radiotherapy, Conformal. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15566679.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


6. Craver RD, Lipscomb JT, Suskind D, Velez MC: Malignant teratoma of the thyroid with primitive neuroepithelial and mesenchymal sarcomatous components. Ann Diagn Pathol; 2001 Oct;5(5):285-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant teratoma of the thyroid with primitive neuroepithelial and mesenchymal sarcomatous components.
  • A 15-year-old black girl had a near total resection of a malignant thyroid teratoma with bilateral nodal involvement and mediastinal extension.
  • A predominant neuroepithelial pattern had ependymal rosettes and mitoses, stained for neuron-specific enolase, neuron-specific B tubulin, and synaptophysin.
  • A malignant spindle cell component stained for smooth-muscle actin, muscle actin, and to a lesser extent S-100.
  • Loose myxoid tissue resembled primitive cartilage.
  • The tumor from the left and right thyroid lobes exhibited trisomy 8, the right also had hyperdiploid cell lines.
  • She was treated with aggressive combination chemotherapy and radiation.
  • Presently there is no residual disease 16 months after diagnosis.
  • Malignant thyroid teratoma is an aggressive tumor, with 15 of 27 reported patients dying 2 weeks to 3 years after diagnosis.
  • Survivors have been treated with total or subtotal resection, combination chemotherapy with agents effective in the treatment of germ cell tumors as well as sarcomas, and radiation for either recurrent or residual disease.
  • The heterologous elements, lacking MIC2 staining and t(11;22), support the diagnosis of malignant teratoma rather than a neuroepithelial tumor.
  • Trisomy 8 is the first cytogenetic abnormality described in malignant thyroid teratoma.
  • Therapy should be tailored to the management of all transformed histologies.
  • [MeSH-major] Neuroectodermal Tumors, Primitive / diagnosis. Sarcoma / diagnosis. Teratoma / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Aneuploidy. Antineoplastic Combined Chemotherapy Protocols. Biomarkers, Tumor / analysis. Biopsy, Needle. Chemotherapy, Adjuvant. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Humans. Image Cytometry. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company
  • (PMID = 11598856.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Number-of-references] 34
  •  go-up   go-down


7. Hammond RR, Duggal N, Woulfe JM, Girvin JP: Malignant transformation of a dysembryoplastic neuroepithelial tumor. Case report. J Neurosurg; 2000 Apr;92(4):722-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a dysembryoplastic neuroepithelial tumor. Case report.
  • Computerized tomography (CT) scanning revealed a superficial hypodense nonenhancing lesion in the midleft frontal convexity, with some remodeling of the overlying skull.
  • He received no chemotherapy or radiation therapy and remained well for 11 years.
  • A Grade IV astrocytoma was resected, and within the malignant tumor was a superficial area reminiscent of a dysembryoplastic neuroepithelial tumor (DNT).
  • This case is the first documented example of malignant transformation of a DNT.
  • It serves as a warning of the potential for malignant transformation in this entity, which has been traditionally accepted as benign.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Frontal Lobe / pathology. Glioblastoma / pathology. Neoplasms, Neuroepithelial / pathology
  • [MeSH-minor] Adult. Astrocytoma / pathology. Electroencephalography. Epilepsies, Partial / diagnosis. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local / pathology. Neuroglia / pathology. Neurons / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10761668.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


8. Rushing EJ, Thompson LD, Mena H: Malignant transformation of a dysembryoplastic neuroepithelial tumor after radiation and chemotherapy. Ann Diagn Pathol; 2003 Aug;7(4):240-4
Hazardous Substances Data Bank. LOMUSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a dysembryoplastic neuroepithelial tumor after radiation and chemotherapy.
  • We describe a case of anaplastic astrocytoma in a 14-year-old boy arising at the site of a dysembryoplastic neuroepithelial tumor (DNT) 3 years after combined radiation and chemotherapy.
  • The subtotally excised superficial right temporoparietal tumor was originally diagnosed as mixed oligoastrocytoma in 1974; the patient was treated with radiation therapy postoperatively.
  • One year later he underwent a craniotomy to remove cyst fluid and no change was reported in the size of the residual tumor.
  • Postoperatively, he received a 6-week course of chemotherapy (lovustine, CCNU).
  • He remained clinically and radiographically stable until 3 years later, when seizure activity returned and imaging studies were consistent with tumor recurrence.
  • This is the first documented case of malignant transformation of DNT following radiation and adjuvant chemotherapy.
  • The implications of malignant transformation in subtotally excised complex DNTs and the intriguing issue of the contribution of radiation/chemotherapy are discussed.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Neoplasms, Neuroepithelial / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Agents, Alkylating / therapeutic use. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Craniotomy. Fatal Outcome. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Lomustine / therapeutic use. Male

  • Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12913847.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


9. Tsuboi Y, Kurimoto M, Nagai S, Kamiyama H, Endo S: Malignant transformation of oligoastrocytoma: a case report. Brain Tumor Pathol; 2007;24(2):63-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of oligoastrocytoma: a case report.
  • We report a case of oligoastrocytoma resembling dysembryoplastic neuroepithelial tumor (DNT) with malignant transformation.
  • Magnetic resonance imaging (MRI) revealed an extensive left temporal lobe tumor.
  • She underwent partial resection of the tumor under awake surgery, while preserving her language function.
  • The surgical specimen showed that the majority of the tumor was composed of a glioneuronal element.
  • Therefore, our first pathological diagnosis was oligoastrocytoma and DNT.
  • She then underwent radiation therapy.
  • The tumor recurred at the left temporal lobe in June 2005.
  • The pathological diagnosis was anaplastic oligoastrocytoma with a MIB-1 staining index of 79%.
  • She received PAV (procarvazine, ACNU, and vincristine) chemotherapy, and the tumor subsided transiently.
  • The authors concluded that this tumor could be a malignant transformation of oligoastrocytoma mimicking DNT, and we wish to give warning that the presence of a glioneuronal component is not an absolute benign hallmark.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Transformation, Neoplastic. Diagnosis, Differential. Female. Humans. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Neurosurgical Procedures. Radiotherapy

  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095133.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Terasaki M, Bouffet E, Katsuki H, Fukushima S, Shigemori M: Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors. Surg Neurol; 2008 Jan;69(1):46-50
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors.
  • BACKGROUND: The aim of this study was to determine the response and toxicity of patients with recurrent or treatment-induced brain tumors to TMZ and oral VP-16.
  • METHODS: Eleven patients with recurrent or treatment-induced malignant CNS tumors, including treatment-induced PNET (in 1 patient), brainstem glioma (in 3 patients; 1 with treatment-induced, 2 with recurrence), recurrent anaplastic astrocytoma (in 3 patients), and recurrent glioblastoma (in 4 patients) were evaluated in a pilot study of TMZ and oral VP-16 chemotherapy.
  • RESULTS: None experienced major acute toxicity related to TMZ and oral VP-16 during a total of 52 treatment courses.
  • Five (45%) of 11 patients showed a PR to treatment.
  • Among the 11 patients enrolled, 7 patients are alive with disease at a median of 9 months from time of study entry.
  • The histologic subtype of the tumor, its location, and its maximum response to chemotherapy did not have an impact on the duration of disease control.
  • CONCLUSION: This limited pilot study confirms the innocuousness and the activity of the combination of TMZ and oral VP-16 in recurrent malignant brain tumors.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Etoposide / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neoplasms, Neuroepithelial / drug therapy. Neoplasms, Second Primary / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Pilot Projects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18054615.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


11. Choi YL, Suh YL, Kim D, Ko YH, Sung CO, Lee JI: Malignant lymphoma of the central nervous system: difficult histologic diagnosis after glucocorticoid therapy prior to biopsy. Clin Neuropathol; 2006 Jan-Feb;25(1):29-36
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma of the central nervous system: difficult histologic diagnosis after glucocorticoid therapy prior to biopsy.
  • Four cases of central nervous system (CNS) lymphoma are reported which presented obstacles in diagnosis due to steroid treatment prior to biopsy.
  • Malignant lymphoma of the CNS may be indistinguishable from other conditions, even in view of the gravity of the diagnosis.
  • However, the molecular assessment of paraffin-embedded tissues revealed the monoclonal IgH gene rearrangement, which allowed the confident diagnosis of B cell lymphoma.
  • The histopathological findings of the present cases suggest that the tumor cells might be selectively destroyed by steroid treatment, which may render diagnosis impossible.
  • Thus, molecular genetic investigation constitutes an important tool for establishing a diagnosis of CNS lymphoma obscured by steroid administration.
  • This is especially true in cases where a paucity of tumor cells is observed or when monoclonality fails to be demonstrated by immunohistochemical tests.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / drug therapy. Glucocorticoids / therapeutic use. Lymphoma / diagnosis. Lymphoma / drug therapy
  • [MeSH-minor] Aged. Dexamethasone / therapeutic use. Diagnosis, Differential. Female. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Glioblastoma / pathology. Glioma / pathology. Humans. Male. Neoplasms, Neuroepithelial / pathology. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465772.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glucocorticoids; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


12. VĂ©drine PO, Coffinet L, Temam S, Montagne K, Lapeyre M, Oberlin O, Orbach D, Simon C, Sommelet D: Mucoepidermoid carcinoma of salivary glands in the pediatric age group: 18 clinical cases, including 11 second malignant neoplasms. Head Neck; 2006 Sep;28(9):827-33
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of salivary glands in the pediatric age group: 18 clinical cases, including 11 second malignant neoplasms.
  • RESULTS: Treatment included surgery or radiotherapy, or both.
  • Eleven patients had been previously treated by radiotherapy and/or chemotherapy for a first malignant tumor, specifically, lymphoid leukemia (n = 4), lymphoma (n = 3), brain tumor (n = 2), sarcoma (n = 1), and retinoblastoma (n = 1).
  • Treatment involves surgical removal of the tumor plus radiotherapy, according to histologic staging.
  • The survival rate does not differ in the subgroup of patients with MEC as a secondary tumor.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Lymphoma / pathology. Male. Neoplasms, Neuroepithelial / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Rhabdomyosarcoma / pathology

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley Periodicals, Inc.
  • (PMID = 16783829.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


13. De Tommasi A, De Tommasi C, Occhiogrosso G, Cimmino A, Parisi M, Sanguedolce F, Ciappetta P: Primary intramedullary primitive neuroectodermal tumor (PNET)--case report and review of the literature. Eur J Neurol; 2006 Mar;13(3):240-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intramedullary primitive neuroectodermal tumor (PNET)--case report and review of the literature.
  • Following the WHO 2000 classification, PNETs have been considered embryonal tumors composed of undifferentiated neuroepithelial cells with a capacity of differentiation into different cellular lines, such as astrocytic, ependymal, melanotic and muscular.
  • They have been considered to arise from a neoplastic transformation of primitive neuroepithelial cells, thereby making their presence possible in any part of the central nervous system.
  • The optimal treatment for these malignant tumors is not yet clear, although, over the years, radiotherapy has been considered the best treatment for spinal PNETs.
  • The described case is that of a 38-year-old man with a primary intra-extramedullary PNET, treated by laminectomy, open biopsy and chemotherapy.
  • The patient, 18 months after the onset of his symptomatology, died without cerebral tumor involvement.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618339.001).
  • [ISSN] 1351-5101
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 25
  •  go-up   go-down


14. Unal E, Koksal Y, Vajtai I, Toy H, Kocaogullar Y, Paksoy Y: Astroblastoma in a child. Childs Nerv Syst; 2008 Feb;24(2):165-8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Astroblastoma, an uncommon neuroepithelial tumor, typically presents in young adults as a well-circumscribed cortical or subcortical spherical mass.
  • Total removal of the tumor mass was performed, and a diagnosis of high grade (malignant) variant of astroblastoma was made.
  • Postoperatively, the patient received radiation therapy, for a period of 11 weeks, followed by chemotherapy.
  • PROGNOSIS: The best treatment modality for astroblastoma is surgical resection if possible, whereas adjuvant therapy (radiotherapy and/or chemotherapy) can be considered in high-grade astroblastomas, with a close follow-up for all cases.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasms, Neuroepithelial / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Combined Modality Therapy. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Radiotherapy

  • Genetic Alliance. consumer health - Astroblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1998 Oct;40(1):59-65 [9874187.001]
  • [Cites] Brain Pathol. 2000 Jul;10 (3):342-52 [10885653.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jun;146(6):629-33 [15168232.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Feb;23(2):243-7 [11847049.001]
  • [Cites] Neurocirugia (Astur). 2006 Feb;17(1):60-3 [16565782.001]
  • [Cites] Childs Nerv Syst. 2005 Mar;21(3):211-20 [15654633.001]
  • [Cites] Neurosurgery. 1989 Jul;25(1):6-13 [2755581.001]
  • [Cites] Acta Neuropathol. 1989;78(5):472-83 [2683559.001]
  • [Cites] Neuropathology. 2006 Feb;26(1):72-81 [16521483.001]
  • (PMID = 17653728.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Fukumoto M, Takahashi JA, Murai N, Ueba T, Kono K, Nakatsu S: Induction of apoptosis in glioma cells: an approach to control tumor growth by blocking basic fibroblast growth factor autocrine loop. Anticancer Res; 2000 Nov-Dec;20(6A):4059-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of apoptosis in glioma cells: an approach to control tumor growth by blocking basic fibroblast growth factor autocrine loop.
  • Glioma is a group of neoplasms derived from neuroepithelial tissue.
  • Among various glioma-derived growth factors, we have found that basic fibroblast growth factor (bFGF) plays an important role in determining malignant trait of human glioma via its autocrine loop.
  • Furthermore, we discuss candidate molecular targets for the therapy of high-grade glioma by blocking the autocrine loop of bFGF.
  • [MeSH-minor] Animals. Cell Division / drug effects. Cell Division / physiology. Growth Inhibitors / pharmacology. Humans

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11131673.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Growth Inhibitors; 103107-01-3 / Fibroblast Growth Factor 2
  • [Number-of-references] 54
  •  go-up   go-down


16. Lodi R, Setola E, Tonon C, Ambrosetto P, Franceschi E, Crinò L, Barbiroli B, Cortelli P: Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration. Magn Reson Imaging; 2003 Nov;21(9):1003-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomatosis cerebri is a rare form of diffusely infiltrating glioma that is typically resistant to conventional chemotherapy and radiation therapy and carries a poor prognosis.
  • Temozolomide has shown antineoplastic activity against malignant gliomas and more recently was beneficial in one patient with gliomatosis cerebri.
  • Twenty cycles of temozolomide resulted in a marked reduction in choline and scyllo-inositol content, as detected using brain proton MR spectroscopy, indicating reduced tumor cellularity and/or growth rate.
  • A left pyramidal syndrome, present at the start of the treatment, disappeared.
  • Our observation lends support to larger clinical trials evaluating the use of temozolomide to treat this brain tumor.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / drug therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Neoplasms, Neuroepithelial / drug therapy
  • [MeSH-minor] Brain / drug effects. Brain / metabolism. Brain / pathology. Humans. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14684203.001).
  • [ISSN] 0730-725X
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


17. Perkins GH, Schomer DF, Fuller GN, Allen PK, Maor MH: Gliomatosis cerebri: improved outcome with radiotherapy. Int J Radiat Oncol Biol Phys; 2003 Jul 15;56(4):1137-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Gliomatosis cerebri is a rare, diffuse involvement of the central nervous system by a malignant glioma that permeates the brain extensively without destroying the neural architecture and involves more than two lobes.
  • METHODS AND MATERIALS: Thirty patients who received RT at a single institution and had radiographic follow-up were retrospectively reviewed with respect to outcome, radiation parameters, extent of surgery, and chemotherapy.
  • RESULTS: The median age at diagnosis was 38.6 years (range 16-68).
  • The mean radiation dose was 54.9 Gy, given in a mean of 28 fractions.
  • The median time to progression was 10 months, and it was significantly longer for patients <40 years old (p = 0.0007) and for patients having a tumor histologic subtype other than glioblastoma (p = 0.01).
  • Extensive surgery, administration of chemotherapy, or increased RT volume improved neither overall survival nor the time to disease progression.
  • Patients who are young and have a nonglioblastoma tumor histologic subtype perform more favorably.
  • In this analysis, no role for chemotherapy, extensive surgery, or whole-brain RT was found.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Neoplasms, Neuroepithelial / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12829152.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 77050-02
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


18. Schmidt AL, Brunetto AL, Schwartsmann G, Roesler R, Abujamra AL: Recent therapeutic advances for treating medulloblastoma: focus on new molecular targets. CNS Neurol Disord Drug Targets; 2010 Jul;9(3):335-48
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent therapeutic advances for treating medulloblastoma: focus on new molecular targets.
  • Medulloblastoma is the most common malignant brain tumor in children.
  • This malignant tumor of the cerebellum commonly affects children and is believed to arise from the precursor cells of the external granule layer or neuroepithelial cells from the cerebellar ventricular zone of the developing cerebellum.
  • The standard treatment, consisting of surgery, craniospinal radiotherapy and chemotherapy, still provides a poor overall survival for infants and young children.
  • Therefore, understanding the oncogenic pathways that lead to medulloblastoma, as well as the identification of specific molecular targets with significant therapeutic implications in order to develop new strategies for therapy, is crucial to improve patient survival without substantially increasing toxicity.
  • In this review, we discuss recent therapeutics for treating medulloblastoma, focusing on new molecular targets, as well as advances in translational studies for the treatment of this malignancy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Brain Neoplasms / metabolism. Drug Delivery Systems / methods. Drug Delivery Systems / trends. Medulloblastoma / drug therapy. Medulloblastoma / metabolism

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20438440.001).
  • [ISSN] 1996-3181
  • [Journal-full-title] CNS & neurological disorders drug targets
  • [ISO-abbreviation] CNS Neurol Disord Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 183
  •  go-up   go-down


19. Terzic M, Dokic M, Stimec B: Immature ovarian teratoma in a young girl: very short course and lethal outcome. A case report. Int J Gynecol Cancer; 2005 Mar-Apr;15(2):382-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They contain several tissues that derive from the three embryologic layers: ectoderm, mesoderm, and endoderm.
  • We report the case of a 17-year-old girl who presented with an immature teratoma of the left ovary that recurred 3 months later as an inoperable malignant neuroepithelial peritoneal tumor resembling a glioblastoma.
  • The very aggressive course and fast lethal outcome could be explained by the patient's refusal to receive chemotherapy after the initial operation.
  • [MeSH-minor] Adolescent. Age Factors. Fatal Outcome. Female. Humans. Prognosis. Time Factors

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15823130.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Tanaka S, Kamitani H, Amin MR, Watanabe T, Oka H, Fujii K, Nagashima T, Hori T: Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drug-resistance genes. J Neurooncol; 2000;46(2):157-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drug-resistance genes.
  • New adjuvant therapy individualized by the results of reverse transcription-polymerase chain reaction (RT-PCR) for drug-resistance genes has been used to treat malignant gliomas.
  • Protocol studies for malignant gliomas were not so encouraging in their therapeutic results because of heterogeneity and the various drug-sensitivities of the tumors.
  • Individualization of glioma therapy is recommended.
  • Drug-resistance genes messenger ribonucleic acid (mRNA) expressions were investigated in drug-resistant human glioma cell lines derived from U87MG and 46 frozen samples of retrospectively examined neuroepithelial tumors (12 low grade neuroepithelial tumors, 16 Grade III gliomas, 11 glioblastomas, and 7 other malignant neuroepithelial tumors such as medulloblastomas and primitive neuroectodermal tumors) by RT-PCR with the specific primers for O6-methylguanine DNA methyltransferase (MGMT), multidrug-resistance gene 1 (MDR1), multidrug-resistance-associated protein (MRP), and glutathione-S-transferase-pi (GST-pi).
  • Thirty-seven preliminary individual adjuvant therapies (IAT) based on RT-PCR results, mainly in MGMT expression, were performed on 30 consecutive patients with neuroepithelial tumors.
  • In the preliminary IAT, 17 of 32 evaluable therapies had a partial or complete response (53.1% response rate).
  • Our IAT based on RT-PCR seemed to be more effective than conventional therapies for malignant gliomas.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / genetics. Chemotherapy, Adjuvant. Drug Resistance, Neoplasm / genetics. Glioma / drug therapy. Glioma / genetics
  • [MeSH-minor] ATP-Binding Cassette Transporters / metabolism. ATP-Binding Cassette, Sub-Family B, Member 1 / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Drug Screening Assays, Antitumor / methods. Humans. Immunohistochemistry. Middle Aged. Multidrug Resistance-Associated Proteins. Nimustine / therapeutic use. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Prospective Studies. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 1994;127(1-2):55-9 [7942182.001]
  • [Cites] Neurosurgery. 1998 Apr;42(4):709-20; discussion 720-3 [9574634.001]
  • [Cites] Am J Pathol. 1996 Sep;149(3):853-8 [8780389.001]
  • [Cites] J Neurosurg Sci. 1990 Jul-Dec;34(3-4):257-9 [1965905.001]
  • [Cites] J Urol. 1996 Aug;156(2 Pt 1):506-11 [8683726.001]
  • [Cites] Nature. 1985 Aug 29-Sep 4;316(6031):817-9 [2863759.001]
  • [Cites] Int J Cancer. 1993 Aug 19;55(1):76-81 [8393842.001]
  • [Cites] Science. 1983 Sep 23;221(4617):1285-8 [6137059.001]
  • [Cites] Neurosurgery. 1997 Aug;41(2):434-40; discussion 440-1 [9257312.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):7160-4 [1976252.001]
  • [Cites] Neurosurg Rev. 1984;7(1):13-22 [6379509.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2563-8 [2174303.001]
  • [Cites] J Neurooncol. 1992 Oct;14(2):159-68 [1331350.001]
  • [Cites] Acta Neuropathol. 1989;79(2):144-8 [2556881.001]
  • [Cites] Curr Opin Neurol Neurosurg. 1992 Dec;5(6):808-12 [1467571.001]
  • [Cites] Anticancer Res. 1996 Jul-Aug;16(4A):2079-82 [8712746.001]
  • [Cites] Neurosurgery. 1997 Oct;41(4):776-83; discussion 783-5 [9316038.001]
  • [Cites] Jpn J Cancer Res. 1996 Dec;87(12 ):1263-70 [9045962.001]
  • [Cites] Ann Oncol. 1992 Jun;3(6):423-33 [1498059.001]
  • [Cites] Clin Cancer Res. 1995 Dec;1(12):1537-43 [9815954.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):372-7 [8903480.001]
  • [Cites] Clin Neuropathol. 1997 Jan-Feb;16(1):34-6 [9020393.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] J Neurosurg. 1992 Mar;76(3):507-12 [1346632.001]
  • [Cites] Int J Cancer. 1994 Sep 15;58(6):860-4 [7927879.001]
  • [Cites] Ital J Neurol Sci. 1992 Dec;13(9):717-22 [1483854.001]
  • [Cites] J Neurooncol. 1991 Oct;11(2):165-70 [1744684.001]
  • [Cites] Cancer Res. 1992 Jan 15;52(2):307-13 [1728404.001]
  • [Cites] Adv Cancer Res. 1972;16:97-140 [4628253.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3416-20 [8324751.001]
  • [Cites] Mol Carcinog. 1991;4(6):482-8 [1793486.001]
  • [Cites] Acta Neuropathol. 1991;82(6):516-9 [1723831.001]
  • [Cites] Neurol Med Chir (Tokyo). 1996 Aug;36(8):555-8; discussion 558-9 [8831197.001]
  • [Cites] J Neurosurg. 1987 Mar;66(3):372-8 [3469331.001]
  • [Cites] Am J Clin Oncol. 1994 Oct;17(5):437-43 [8092118.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Jpn J Clin Oncol. 1992 Jun;22(3):143-9 [1518162.001]
  • [Cites] Surg Neurol. 1995 Nov;44(5):462-8; discussion 468-70 [8629231.001]
  • [Cites] Curr Opin Oncol. 1996 May;8(3):188-95 [8804816.001]
  • [Cites] J Interferon Res. 1990 Apr;10 (2):141-51 [2140395.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(2):686-90 [2405387.001]
  • [Cites] J Neurosurg. 1983 Feb;58(2):170-6 [6848672.001]
  • [Cites] J Neurosurg. 1991 Dec;75(6):941-6 [1682428.001]
  • [Cites] Int J Cancer. 1996 Oct 21;69(5):420-5 [8900378.001]
  • (PMID = 10894369.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / Antineoplastic Agents; 0 / Multidrug Resistance-Associated Proteins; 0 / RNA, Messenger; 0S726V972K / Nimustine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


21. Wei S, Carroll W, Lazenby A, Bell W, Lopez R, Said-Al-Naief N: Sinonasal teratocarcinosarcoma: report of a case with review of literature and treatment outcome. Ann Diagn Pathol; 2008 Dec;12(6):415-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal teratocarcinosarcoma: report of a case with review of literature and treatment outcome.
  • Sinonasal teratocarcinosarcoma is a highly malignant, polymorphous neoplasm that combines features of carcinosarcoma and teratoma.
  • Computerized tomography scans and magnetic resonance imaging revealed a large mass filling the left nasal cavity and extending to the cribriform plate with involvement of the ethmoid sinuses, lamina papyracea, and orbit.
  • The patient underwent a complex procedure for a T3N0 tumor.
  • Histologic examination revealed a heterogeneous admixture of epithelial, mesenchymal, and neuroepithelial elements.
  • Immature neuroepithelium and olfactory neuroblastomalike tissue are highlighted with neuroendocrine markers.
  • Postoperatively, the patient had a rapid local recurrence of the tumor and underwent reexcision, and was treated with radiotherapy and chemotherapy.
  • Twelve months after his primary resection, computerized tomography scans revealed an intrathoracic tumor with dominant mass in the left hilum and metastases to the mediastinum, left pleural space, and both lungs.
  • Among 54 cases of reported sinonasal teratocarcinosarcoma, 67% of patients with initial single surgical resection and 80% of patients primarily treated with radiotherapy had recurrence, or metastatsis, or unresponsiveness to treatment.
  • Almost half of the patients died of tumor within 3 years of diagnosis, despite aggressive therapy.
  • Seventy percent of the patients who survived more than 1 year had the initial therapeutic regiments of combined surgery and adjuvant therapies, suggesting that aggressive therapeutic approaches may improve the treatment outcome.
  • [MeSH-major] Carcinosarcoma / diagnosis. Carcinosarcoma / therapy. Nose Neoplasms / diagnosis. Nose Neoplasms / therapy. Teratoma / diagnosis. Teratoma / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Paranasal Sinuses / pathology. Paranasal Sinuses / surgery. Prognosis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18995206.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down






Advertisement